Observational studyEuropean stroke journal2026
Endovascular treatment in patients with renal dysfunction: results of the MR CLEAN Registry.
Observational study in European stroke journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionIt is unclear whether renal function is associated with outcome in patients with ischaemic stroke treated with EVT, as findings in existing literature have been inconsistent. We studied the association between renal function and outcomes in EVT-treated patients. PATIENTS AND
methodsWe used data from the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) Registry. We assessed the association between renal function using estimated glomerular filtration rate (eGFR) and functional outcome measured with the mRS score, mortality and the occurrence of sICH in ischaemic stroke patients treated with EVT. We used ordinal regression modelling to estimate common odds ratios (cOR) per 10-unit decrease in eGFR, adjusted for known prognostic factors.
resultsWe analysed 4466 patients included between March 2014 and December 2018. Patients with lower eGFR were older, had more severe strokes at baseline, more comorbidities and higher pre-stroke mRS scores (all P < .001). In unadjusted analyses, higher eGFR was associated with better 3-month functional outcome (cOR 1.18; 95% CI, 1.15-1.21) and lower mortality (cOR 0.81; 95% CI, 0.78-0.83). After adjusting for demographic factors, only the association between eGFR and mortality remained significant. After further adjustment for medical history and comorbidities, no association was found between eGFR and mRS (adjusted odds ratio [aOR] 0.99; 95% CI, 0.96-1.02) or mortality (aOR 0.96; 95% CI, 0.93-1.01). There was no association between eGFR and sICH (cOR 0.95; 95%CI, 0.89-1.01, aOR 0.99; 95% CI, 0.93-1.06).
conclusionRenal function was not an independent modifier of outcome after EVT for ischaemic stroke although eGFR may serve as a predictor of increased risk of disability and mortality. Based on these results, renal function alone should not determine eligibility for EVT in ischaemic stroke patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.